Texas Oncology-Fort Worth Cancer Center

Summary

Texas Oncology-Fort Worth Cancer Center is a medical facility located in Fort Worth, Texas. This center is recognized for care of Ovarian Cancer, Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer and other specialties. Texas Oncology-Fort Worth Cancer Center is involved with conducting 98 clinical trials across 114 conditions. There are 5 research doctors associated with this hospital, such as Noelle Cloven, MD, Stephen Richey, Chi M Pham, and Harris Naina, MD.

Top PIs

Clinical Trials running at Texas Oncology-Fort Worth Cancer Center

Ovarian Cancer

Endometrial Cancer

Melanoma

Fallopian Tube Cancer

Cervical Cancer

Relapse

Follicular Lymphoma

Small Cell Lung Cancer

Stomach Cancer

Breast Cancer

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Avutometinib + Defactinib

for Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Recruiting

2 awards

Phase 3

8 criteria

Carboplatin + Mirvetuximab Soravtansine

for Ovarian Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States. Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Recruiting

1 award

Phase 2

4 criteria